Hepatocellular Carcinoma Identification Using Delta-HLD
Recruiting
Observational Study
Hepato Cellular Carcinoma (HCC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- Epiliquid Holding, Inc · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specif…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls)
* Willing and able to provide informed consent
* Available paired plasma and liver tissue sample
Exclusion Criteria:
* Other active cancers
* Prior liver transplantation
* Kno…
Contacts